Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL

Nurix Therapeutics, Inc. (NRIX) announced an update on their ongoing clinical study.

The phase 3 study “A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)” will compare Nurix Therapeutics, Inc.’s NX-5948 to pirtobrutinib in hard-to-treat blood cancers. It aims to show whether Nurix’s drug can match or beat an approved rival in patients who have already failed prior BTK therapy.

The trial tests two oral drugs given once a day. NX-5948 (bexobrutideg) is Nurix’s experimental therapy, while pirtobrutinib (JAYPIRCA) is an established non-covalent BTK blocker, used here as an active control and key benchmark.

This is an interventional phase 3 trial with patients randomly assigned to one of the two drugs. It is open-label, so doctors and patients know which drug they get, and the main goal is to see which option works better and stays safe for treatment of relapsed or refractory CLL/SLL.

The study was first submitted on March 31, 2026, and the latest update was filed on April 6, 2026. Recruitment has not started yet, so primary and final completion dates are still ahead and will be critical future markers for when top-line data could reach the market.

For investors, this update signals Nurix’s push into late-stage development in CLL/SLL, a large market already served by BTK drugs like pirtobrutinib. Clear success versus JAYPIRCA could support a rerating of NRIX, while any delay or underperformance may favor incumbents and weigh on the stock in a crowded hematology space.

The study is not yet recruiting but is actively updated, and further details are available on the ClinicalTrials portal.

To learn more about NRIX’s potential, visit the Nurix Therapeutics, Inc. drug pipeline page.